Physician profile
Lori K Ramirez
NPI 1508952615
$37,815.83
in general payments reported to CMS, 2019-2025
39 companies · $14K in 2025
The $14K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $171 · 2021: $179 · 2022: $130 · 2023: $11K · 2024: $12K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Consulting Fee: $7,650 · Food and Beverage: $4,379 · Travel and Lodging: $3,235 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,422.32 |
| Consulting Fee | $7,650.00 |
| Food and Beverage | $4,379.06 |
| Travel and Lodging | $3,234.85 |
| Education | $212.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30,423.60 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $4,410.08 | 2022-2025 | |
| Ucb, INC. | $657.30 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $425.53 | 2024-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $262.09 | 2019-2025 | Aklief, Nemluvio |
| Regeneron Healthcare Solutions, INC. | $174.63 | 2024-2025 | Dupixent, Libtayo |
| Abbvie INC. | $162.70 | 2020-2025 | |
| Janssen Biotech, INC. | $140.64 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $134.02 | 2019-2025 | Ebglyss, Taltz, Jardiance |
| Biofrontera INC. | $129.10 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Allergan, INC. | $111.61 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $88.64 | 2023-2024 | Sotyktu |
| Botanix Sb INC | $72.77 | 2025 | Sofdra |
| Amgen INC. | $67.70 | 2019-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $65.61 | 2022-2025 |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.